Cardiovascular Medication Use Before First Myocardial Infarction
Large randomised trials have shown that cardiovascular medications prescribed to patients at high cardiovascular risk are effective in reducing the incidence of cardiovascular events. Their use is recommended in the United Kingdom and international guidelines (e.g. the National Institute of Clinical Excellence). However, these medications do not prevent cardiovascular events in all patients and there is now a body of research investigating the effects of cardiovascular medications on outcomes in myocardial infarction (MI), including clinical presentation, infarct size and post-MI mortality. However, the independent effects of cardiovascular drugs on post-MI all cause mortality are unclear, and there are limitations to many of the published studies in terms of their cardiovascular drug exposure data. This project utilizes prospectively collected data on cardiovascular drug use, and links to MI data from hospital and mortality records.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Cardiovascular Medication Prescriptions Before First Myocardial Infarction in Patients With and Without Previously Diagnosed Atherosclerotic Disease: an Analysis of Linked Prospectively Collected Electronic Healthcare Records|
- All cause mortality [ Time Frame: Up to seven years ] [ Designated as safety issue: No ]All cause mortality, using Office for National Statistics (ONS) mortality statistics
- Re-infarction [ Time Frame: One year after initial myocardial infarction ] [ Designated as safety issue: No ]Reinfarction will be measured based on data from the General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Myocardial Ischaemia National Audit Project (MINAP) and Office for National Statistics (ONS) mortality data.
- Myocardial infarciton (MI) type [ Time Frame: Measured at baseline ] [ Designated as safety issue: No ]Diagnosed ST-elevation MI or non ST-elevation myocardial infarction
- Infarct size [ Time Frame: Measured at baseline ] [ Designated as safety issue: No ]Infarct size, as measured by levels of peak troponin in hospital, as recorded in the MINAP data source.
|Study Start Date:||September 2009|
|Estimated Study Completion Date:||September 2014|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01692795
|London School of Hygiene and Tropical Medicine|
|London, United Kingdom, WC1E 7HT|
|Principal Investigator:||Emily Herrett, MSc||London School of Hygiene and Tropical Medicine|
|Study Director:||Harry Hemingway, FRCP||University College, London|